Clinical Trials


A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

This study has been completed
Hoffmann-La Roche

Information provided by (Responsible Party)
Hoffmann-La Roche Identifier

First received: November 2, 1999
Last updated: May 15, 2017
Last Verified: July 2005
History of Changes


To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.

Condition Intervention Phase
Cytomegalovirus Retinitis
HIV Infections

Drug : Valganciclovir
Drug : Ganciclovir
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment

Further study details as provided by Hoffmann-La Roche:

Study Start Date: January 1997
Study Completion Date: December 2002
Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)



Ages Eligible for Study: 14 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Documented AIDS diagnosis
  • Newly diagnosed peripheral CMV retinitis
  • More than 3 weeks of previous therapy for CMV retinitis

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002377


United States, California
Univ of California / Irvine
Irvine, California, United States, 92697
Univ of California / San Diego / Dept of Pediatrics
La Jolla, California, United States, 92093
Univ of California / San Diego Treatment Ctr
San Diego, California, United States, 92103
Davies Med Ctr / Institute for HIV Research
San Francisco, California, United States, 94114
Kaiser Permanente Med Ctr
San Francisco, California, United States, 94115
QUEST Clinical Research
San Francisco, California, United States, 94115
United States, District of Columbia
Dr Alan Palestine
Washington, D.C., District of Columbia, United States, 20006
United States, Florida
Univ of Miami School of Medicine
Miami, Florida, United States, 33136
United States, Georgia
Emory Eye Clinic
Atlanta, Georgia, United States, 30322
United States, Massachusetts
New England Med Ctr
Boston, Massachusetts, United States, 02111
United States, New York
New York Univ Med Ctr
New York, New York, United States, 10016
St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis
New York, New York, United States, 10019
New York Hosp - Cornell Med Ctr
New York, New York, United States, 10021
United States, North Carolina
Duke Univ Eye Ctr
Durham, North Carolina, United States, 27710
United States, Texas
Austin Infectious Disease Consultants
Austin, Texas, United States, 78705
St Pauls Hosp
Vancouver, British Columbia, Canada
The Toronto Hosp / Dept of Infectious Disease
Toronto, Ontario, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Royal Victoria Hosp
Montreal, Quebec, Canada

Sponsors and Collaborators

Hoffmann-La Roche
More Information

More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00002377   History of Changes  
Other Study ID Numbers: WV15376  
Study First Received: November 2, 1999  
Last Updated: May 15, 2017  

Additional relevant MeSH terms:
Cytomegalovirus Retinitis
Ganciclovir triphosphate processed this data on June 02, 2020
This information is provided by